AU1717495A
(en)
*
|
1994-02-16 |
1995-09-04 |
Shionogi & Co., Ltd. |
Process for producing 3-isoxazolecarboxylic acid
|
CA2212836C
(fr)
*
|
1995-02-13 |
2003-08-12 |
G.D. Searle & Co. |
Isoxazoles substitues utilisables dans le traitement d'inflammations
|
US6512121B2
(en)
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
US5968974A
(en)
*
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
EP1640003A2
(fr)
*
|
1996-02-13 |
2006-03-29 |
G.D. SEARLE & CO. |
Compositions renfermant un inhibiteur de cyclooxygenase-2 et un antagoniste de recepteur de leucotriene b4
|
EP0892791B1
(fr)
*
|
1996-04-12 |
2003-03-05 |
G.D. Searle & Co. |
N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPANAMIDE et son SEL de SODIUM UTILISABLES COMME PRECURSEURS DES INHIBITEURS DU COX-2
|
DK0920422T3
(da)
|
1996-08-14 |
2003-03-17 |
Searle & Co |
Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
WO1999030721A1
(fr)
|
1997-12-17 |
1999-06-24 |
Cornell Research Foundation, Inc. |
. inhibition de la cyclooxygenase-2
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
NZ333399A
(en)
*
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
US6194431B1
(en)
*
|
1998-04-14 |
2001-02-27 |
Paul D. Rubin |
Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
|
WO2000013685A1
(fr)
*
|
1998-09-08 |
2000-03-16 |
Cornell Research Foundation, Inc. |
Traitement des maladies inflammatoires de la tete et du cou par des inhibiteurs de cyclooxygenase-2
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
PT1150960E
(pt)
*
|
1999-12-08 |
2005-06-30 |
Pharmacia Corp |
Formas cristalinas polimorficas do celecoxib
|
ATE283048T1
(de)
*
|
1999-12-08 |
2004-12-15 |
Pharmacia Corp |
Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
|
US20040062803A1
(en)
*
|
1999-12-22 |
2004-04-01 |
Hedden David B. |
Sustained-release formulation of a cyclooxygenase-2 inhibitor
|
US6579880B2
(en)
|
2000-06-06 |
2003-06-17 |
Ortho-Mcneil Pharmaceutical, Inc. |
Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
|
CA2414674A1
(fr)
*
|
2000-07-13 |
2002-01-24 |
Pharmacia Corporation |
Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
CN1638739A
(zh)
*
|
2000-08-18 |
2005-07-13 |
法玛西雅厄普约翰美国公司 |
治疗成瘾性障碍的化合物
|
US8680081B2
(en)
*
|
2000-08-29 |
2014-03-25 |
Peter Van Patten |
Prophylactic treatment of migraine
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
CA2422064A1
(fr)
*
|
2000-09-18 |
2002-03-21 |
Merck & Co., Inc. |
Traitement de l'inflammation au moyen d'une combinaison d'un inhibiteur de cyclooxygenase-2 et d'un antagoniste d'integrine alpha-v
|
EP1363649A1
(fr)
*
|
2000-12-15 |
2003-11-26 |
Pharmacia Corporation |
Inhibition selective de cox-2 au moyen d'extraits de plantes non comestibles
|
WO2002047706A2
(fr)
*
|
2000-12-15 |
2002-06-20 |
Pharmacia Corporation |
Inhibition sélective de la cox-2 au moyen d'extraits végétaux
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
WO2002062391A2
(fr)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Methode d'utilisation d'un inhibiteur de la cyclooxygenase-2 et de steroides sexuels dans une polytherapie pour traiter et prevenir la dysmenorrhee
|
AU2002306868A1
(en)
*
|
2001-03-28 |
2002-10-15 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
MY137736A
(en)
|
2001-04-03 |
2009-03-31 |
Pharmacia Corp |
Reconstitutable parenteral composition
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
US20030105144A1
(en)
*
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
EP1390026B1
(fr)
|
2001-05-03 |
2010-05-05 |
Cornell Research Foundation, Inc. |
Traitement de maladies causees par le papillomavirus humain (hpv)
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
TNSN03127A1
(fr)
*
|
2001-05-31 |
2005-12-23 |
Pharmacia Corp |
Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US6589997B2
(en)
*
|
2001-06-29 |
2003-07-08 |
North Shore-Long Island Jewish Health System |
Small-molecule modulators of hepatocyte growth factor/scatter factor activities
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
US20030100594A1
(en)
*
|
2001-08-10 |
2003-05-29 |
Pharmacia Corporation |
Carbonic anhydrase inhibitor
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
BR0212435A
(pt)
*
|
2001-09-10 |
2004-08-17 |
Sugen Inc |
Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
KR20040044990A
(ko)
*
|
2001-09-26 |
2004-05-31 |
파마시아 코포레이션 |
구강내 붕해성 발데콕시브 조성물
|
CN1308315C
(zh)
*
|
2001-10-02 |
2007-04-04 |
法玛西雅公司 |
制备苯磺酰基化合物的方法
|
ATE424388T1
(de)
|
2001-12-06 |
2009-03-15 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
US20030211163A1
(en)
*
|
2002-01-10 |
2003-11-13 |
Chong Kong Teck |
Combination antiviral therapy
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
TW200403072A
(en)
*
|
2002-01-23 |
2004-03-01 |
Upjohn Co |
Combination therapy for the treatment of bacterial infections
|
WO2004026235A2
(fr)
*
|
2002-09-20 |
2004-04-01 |
Transform Pharmaceuticals, Inc. |
Compositions pharmaceutiques presentant une dissolution amelioree
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
WO2003074474A2
(fr)
*
|
2002-03-01 |
2003-09-12 |
University Of South Florida |
Phases solides multicomposants contentant au moins un principe pharmaceutiquement actif
|
BR0307906A
(pt)
*
|
2002-02-22 |
2004-12-21 |
Warner Lambert Co |
Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2
|
TW562937B
(en)
*
|
2002-03-26 |
2003-11-21 |
Nanya Technology Corp |
Method for fast determining defect type of word line
|
EP1492773B1
(fr)
*
|
2002-04-05 |
2009-02-04 |
Cadila Healthcare Ltd. |
4-(heterocyclyl)-benzenesulfoximines, leur procede de preparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de maladies inflammatoires
|
IL164163A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Pharmacia Corp |
Process for preparing a finely self-emulsifiable pharmaceutical composition
|
KR100804827B1
(ko)
*
|
2002-05-17 |
2008-02-20 |
씨제이제일제당 (주) |
티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
|
CN100360117C
(zh)
*
|
2002-06-21 |
2008-01-09 |
转化医药公司 |
具有提高的溶出度的药物组合物
|
KR100465455B1
(ko)
*
|
2002-06-24 |
2005-01-13 |
씨제이 주식회사 |
2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100478467B1
(ko)
|
2002-06-24 |
2005-03-23 |
씨제이 주식회사 |
피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
|
WO2004002409A2
(fr)
*
|
2002-06-27 |
2004-01-08 |
Nitromed, Inc. |
Inhibiteurs selectifs de la cyclooxygenase 2, compositions associees et methodes d'utilisation
|
CA2491479A1
(fr)
*
|
2002-07-02 |
2004-01-15 |
Pharmacia Corporation |
Utilisation d'inhibiteurs selectifs de cyclooxygenase-2 et d'agents thrombolitiques pour le traitement ou la prevention d'un evenement d'occlusion vasculaire
|
KR100467668B1
(ko)
*
|
2002-08-07 |
2005-01-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
EP1545520A4
(fr)
|
2002-08-22 |
2008-07-16 |
Cornell Res Foundation Inc |
Inhibiteurs de cox-2 multifonctionnels
|
JP2006514687A
(ja)
*
|
2002-08-30 |
2006-05-11 |
ファルマシア コーポレイション |
再現性のある医薬放出特性を示す医薬固形投与形態
|
KR100484525B1
(ko)
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
EP1562914A1
(fr)
*
|
2002-10-22 |
2005-08-17 |
Merck Frosst Canada & Co. |
Inhibiteurs selectifs de la cyclo-oxygenase-2 liberant de l'oxyde nitrique
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
KR100470075B1
(ko)
|
2002-11-21 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100491317B1
(ko)
*
|
2002-11-26 |
2005-05-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100470076B1
(ko)
*
|
2002-11-27 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
RU2331438C2
(ru)
|
2002-12-13 |
2008-08-20 |
Уорнер-Ламберт Компани Ллс |
Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
MXPA05006792A
(es)
*
|
2002-12-19 |
2006-02-17 |
Pharmacia Corp |
Metodos y composiciones para el tratamiento de infecciones por el virus del herpes utilizando inhibidores selectivos de la ciclooxigenasa-2 o inhibidores de la ciclooxigenasa-2 en combinacion con agentes antivirales.
|
WO2004058354A1
(fr)
*
|
2002-12-20 |
2004-07-15 |
Pharmacia Corporation |
Compositions d'inhibiteurs selectifs de cyclooxygenase-2 et d'inhibiteurs selectifs de recaptage de serotonine dans le traitement ou dans la prevention d'un evenement vaso-occlusif
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
US20040176378A1
(en)
*
|
2003-02-12 |
2004-09-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
JP2006520779A
(ja)
*
|
2003-03-20 |
2006-09-14 |
ファルマシア コーポレイション |
抗炎症薬の分散性処方物
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
US20040214861A1
(en)
*
|
2003-03-28 |
2004-10-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
|
AU2003238668A1
(en)
*
|
2003-04-04 |
2004-10-25 |
Hetero Drugs Limited |
Novel crystalline forms of valdecoxib
|
US20040224940A1
(en)
*
|
2003-04-22 |
2004-11-11 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
|
US20050159403A1
(en)
*
|
2003-04-22 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
|
WO2004093814A2
(fr)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions a base d'un inhibiteur selectif de la cyclooxygenase-2 et d'un bloqueur du canal d'ions sodium pour le traitement de la douleur, de l'inflammation ou de troubles medies par l'inflammation
|
WO2004093896A1
(fr)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions constituees d'un inhibiteur selectif de la cyclooxygenase-2 et d'un modulateur des canaux ioniques du potassium destinees au traitement de lesions du systeme nerveux central
|
WO2004093813A2
(fr)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions renfermant un inhibiteur selectif a l'egard de la cyclooxygenase 2 et un agent de modulation du calcium pour le traitement de la douleur, de l'inflammation ou de troubles dus a l'inflammation
|
US20040229803A1
(en)
*
|
2003-04-22 |
2004-11-18 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
CA2524610C
(fr)
*
|
2003-05-07 |
2014-03-25 |
Osteologix A/S |
Combinaisons a base de strontium pour la prophylaxie / le traitement d'affections touchant les cartilages et/ou les os
|
PL1534305T3
(pl)
*
|
2003-05-07 |
2007-03-30 |
Osteologix As |
Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
|
WO2004100895A2
(fr)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions comprenant un inhibiteur selectif de la cyclooxygenase-2 et un agoniste des recepteurs actives par les proliferateurs de peroxysomes, pour traiter des troubles d'origine ischemique du systeme nerveux central
|
JP2006528695A
(ja)
*
|
2003-05-14 |
2006-12-21 |
ファルマシア・コーポレーション |
血流量の減少又は中枢神経系の外傷を治療するためのベンゼンスルホンアミド又はメチルスルホニルベンゼン系シクロオキシゲナーゼ−2選択的阻害剤及びコリン作動性作用物質の組成物
|
WO2004103286A2
(fr)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions comprenant un inhibiteur selectif de la cyclooxygenase-2 et un agent cholinergique pour le traitement des reductions du debit sanguin ou des traumatismes affectant le systeme nerveux central
|
US20050159419A1
(en)
*
|
2003-05-14 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
|
WO2004110456A1
(fr)
*
|
2003-05-27 |
2004-12-23 |
Pharmacia Corporation |
Composition reunissant un inhibiteur selectif de la cyclooxygenase-2, un compose xanthinique et un alcool, destinee au traitement de lesions ou de troubles ischemiques relayes par le systeme nerveux central
|
US20060160776A1
(en)
*
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
CA2753318A1
(fr)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Derives pyrroliques substitues
|
WO2005000294A1
(fr)
*
|
2003-06-06 |
2005-01-06 |
Pharmacia Corporation |
Inhibiteur selectif et agent anticonvulsivant utiles pour le traitement des troubles du systeme nerveux central
|
US20050054646A1
(en)
*
|
2003-06-09 |
2005-03-10 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
|
WO2005000297A1
(fr)
*
|
2003-06-24 |
2005-01-06 |
Pharmacia Corporation |
Traitement de migraines accompagnees de nausees
|
WO2005007106A2
(fr)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions renfermant un inhibiteur selectif de la cyclooxygenase 2 et un modulateur du glutamate non-nmda pour le traitement d'une lesion du systeme nerveux central
|
US20050080083A1
(en)
*
|
2003-07-10 |
2005-04-14 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
|
WO2005018541A2
(fr)
*
|
2003-07-11 |
2005-03-03 |
Pharmacia Corporation |
Compositions renfermant un inhibiteur selectif de la cyclo-oxygenase-2 et un agent modulant la serotonine destinees au traitement de lesions du systeme nerveux central
|
WO2005009342A2
(fr)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Methode de traitement ou de prevention de troubles dermatologiques a l'aide d'un seul inhibiteur de la cyclooxygenase-2 ou en combinaison avec un agent de traitement dermatologique, et compositions contenant ceux-ci
|
US20050075341A1
(en)
*
|
2003-07-17 |
2005-04-07 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
US20050085478A1
(en)
*
|
2003-08-22 |
2005-04-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
|
US20050130971A1
(en)
*
|
2003-08-22 |
2005-06-16 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
BRPI0413679A
(pt)
*
|
2003-08-22 |
2006-10-24 |
Pharmacia Corp |
formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia
|
US20050085479A1
(en)
*
|
2003-08-27 |
2005-04-21 |
Pharmacia Corporation |
Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
WO2005023189A2
(fr)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Procede de prevention ou de traitement de la douleur, de l'inflammation, et de troubles lies a l'inflammation avec un inhibiteur selectif de cox-2 en combinaison avec un agent donneur de monoxyde d'azote et compositions en contenant
|
US20050131028A1
(en)
*
|
2003-09-11 |
2005-06-16 |
Pharmacia Corporation |
Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
|
WO2005037193A2
(fr)
*
|
2003-10-03 |
2005-04-28 |
Pharmacia Corporation |
Compositions a base d'inhibiteur selectif de la cyclooxygenase-2 administrees dans des conditions d'hypothermie pour le traitement de lesions ou de troubles du systeme nerveux central induits par une ischemie
|
WO2005044227A1
(fr)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Compositions pharmaceutiques topiques
|
JP2007510756A
(ja)
*
|
2003-11-12 |
2007-04-26 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
中枢神経系介在障害を治療するためのシクロオキシゲナーゼ−2選択的阻害剤及び神経栄養因子調節剤の組成物
|
US7781592B2
(en)
*
|
2003-11-25 |
2010-08-24 |
Cj Cheiljedang Corporation |
Thione derivative, method for the preparation thereof, and pharmaceutical composition containing the same
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
US20050182113A1
(en)
*
|
2003-12-30 |
2005-08-18 |
Venkataraman Sundaram |
Method for preparing diaryl-substituted isoxazole compounds
|
CA2491332A1
(fr)
*
|
2003-12-30 |
2005-06-30 |
Dr. Reddy's Laboratories Ltd. |
Methode de preparation de diarylisoxazoles
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
US20070225333A1
(en)
*
|
2004-04-28 |
2007-09-27 |
Bryans Justin S |
3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
|
US20050272787A1
(en)
*
|
2004-05-19 |
2005-12-08 |
Eswaraiah Sajja |
Process for preparing crystalline form A of valdecoxib
|
WO2006007491A1
(fr)
|
2004-07-01 |
2006-01-19 |
Merck & Co., Inc. |
Inhibiteurs de la kinesine mitotique
|
RU2007101510A
(ru)
*
|
2004-07-22 |
2008-08-27 |
Фармаци Корпорейшн (US) |
Композиции для лечения воспаления и боли с использованием комбинации селективного ингибитора сох-2 и антагониста рецептора ltb4
|
WO2006066968A1
(fr)
|
2004-12-23 |
2006-06-29 |
Glaxo Group Limited |
Composes de pyridine destines au traitement de maladies a mediation par prostaglandine
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
EP2444421A1
(fr)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
Anticorps de la P-Cadherine
|
US20060251702A1
(en)
*
|
2005-05-05 |
2006-11-09 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
WO2006123182A2
(fr)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Sulfones de cyclohexyle pour le traitement du cancer
|
CA2608718A1
(fr)
*
|
2005-05-18 |
2006-11-23 |
Pfizer Limited |
Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine
|
TWI387592B
(zh)
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
JP5161777B2
(ja)
|
2005-09-07 |
2013-03-13 |
アムジェン フレモント インク. |
アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体
|
US8026377B2
(en)
*
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
EP1978964A4
(fr)
|
2006-01-24 |
2009-12-09 |
Merck & Co Inc |
Inhibition de la tyrosine kinase jak2
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008020314A2
(fr)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Formulations de dosage stabilisantes à base de statine
|
JP5328640B2
(ja)
|
2006-04-19 |
2013-10-30 |
ノバルティス アーゲー |
6−o−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにcsf−1rシグナル伝達を阻害する方法
|
KR101412943B1
(ko)
|
2006-06-28 |
2014-06-26 |
아스카 세이야쿠 가부시키가이샤 |
피리딜이소옥사졸 유도체
|
US20090192164A1
(en)
*
|
2006-06-28 |
2009-07-30 |
Aska Pharmaceutical Co., Ltd. |
Treating agent of inflammatory bowel disease
|
TW200811101A
(en)
*
|
2006-07-14 |
2008-03-01 |
Ranbaxy Lab Ltd |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
EP2083831B1
(fr)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008077599A1
(fr)
|
2006-12-22 |
2008-07-03 |
Recordati Ireland Limited |
Thérapie combinée de troubles du tractus urinaire inférieur à l'aide de ligands de l'α2δ et d'ains
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
CA2676413A1
(fr)
*
|
2007-01-19 |
2008-07-31 |
Mallinckrodt Inc. |
Ligands de liaison a la cycloxygenase-2 diagnostiques et therapeutiques
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
WO2009002495A1
(fr)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
|
US8247423B2
(en)
|
2007-07-12 |
2012-08-21 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
MX2010002712A
(es)
|
2007-09-10 |
2010-06-09 |
Calcimedica Inc |
Compuestos que modulan calcio intracelular.
|
WO2009111354A2
(fr)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Inhibiteurs de la tyrosine kinase
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
BRPI0917719A2
(pt)
|
2008-08-27 |
2019-11-19 |
Calcimedica Inc |
compostos que modulam cálcio intracelular
|
EP2177215A1
(fr)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-cristaux de tramadol et NSAID
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
WO2011012622A1
(fr)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Dérivés de benzoxazinone pour traiter des troubles induits par glytl
|
WO2011023753A1
(fr)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Dérivés de benzoxazine inhibiteurs du transport de glycine
|
WO2011046771A1
(fr)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
EP2563759B1
(fr)
|
2010-04-27 |
2022-04-06 |
Calcimedica, Inc. |
Composés qui modulent le calcium intracellulaire
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
WO2011145022A1
(fr)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phénylbenzoylamides
|
EP2584903B1
(fr)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
|
JP5815029B2
(ja)
|
2010-07-09 |
2015-11-17 |
クオンベルゲンセ プハルマセウトイカルス リミテッド |
カルシウムチャネル遮断薬としてのテトラゾール化合物
|
WO2012018754A2
(fr)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
|
EP3587574B1
(fr)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2012030685A2
(fr)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(fr)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina)
|
WO2012087772A1
(fr)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
|
WO2012098400A1
(fr)
|
2011-01-19 |
2012-07-26 |
Convergence Pharmaceuticals Limited |
Dérivés de pipérazine en tant que bloqueurs de canaux calciques cav2.2
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
US20140315786A1
(en)
|
2011-03-18 |
2014-10-23 |
Catabasis Pharmaceuticals, Inc. |
Use of intracellular enzymes for the release of covalently linked bioactives
|
WO2012145471A1
(fr)
|
2011-04-21 |
2012-10-26 |
Merck Sharp & Dohme Corp. |
Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
|
EP2545964A1
(fr)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
WO2013066729A1
(fr)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
EP3919620A1
(fr)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Compositions d'acide nucléique interférent court (sina)
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
PL2925888T3
(pl)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Kompozycje i sposoby do stosowania w leczeniu nowotworów
|
CA2895504A1
(fr)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
|
WO2014120748A1
(fr)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015054283A1
(fr)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Composés qui modulent le calcium intracellulaire
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
EP3268003B1
(fr)
|
2015-03-12 |
2020-07-29 |
Merck Sharp & Dohme Corp. |
Thénopyrazines inhibitrices de l'activité de l'irak4
|
WO2016144846A1
(fr)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine
|
CA2968836A1
(fr)
|
2016-06-13 |
2017-12-13 |
Gilead Sciences, Inc. |
Composes modulant fxr (nr1h4)
|
SI3730487T1
(sl)
|
2016-06-13 |
2022-08-31 |
Gilead Sciences, Inc. |
Azetidinski derivati kot modulatorji FXR (NR1H4)
|
CA3055581C
(fr)
|
2017-03-28 |
2023-03-14 |
Gilead Sciences, Inc. |
Methodes de traitement de la maladie du rein
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
CN108299331A
(zh)
*
|
2018-03-02 |
2018-07-20 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠光降解杂质及其制备、检测方法和应用
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
HRP20240265T1
(hr)
|
2019-01-15 |
2024-05-10 |
Gilead Sciences, Inc. |
Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže
|
US11524005B2
(en)
|
2019-02-19 |
2022-12-13 |
Gilead Sciences, Inc. |
Solid forms of FXR agonists
|
CA3160153A1
(fr)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Inhibiteurs de prmt5
|